A Multiplex Snapback Primer System for the Enrichment and Detection of JAK2 V617F and MPL W515L/K Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

被引:5
|
作者
Wu, Zhiyuan [1 ,2 ]
Zhang, Yunqing [3 ]
Zhang, Xinju [1 ]
Xu, Xiao [1 ]
Kang, Zhihua [4 ]
Li, Shibao [4 ]
Zhang, Chen [2 ]
Su, Bing [5 ]
Guan, Ming [1 ,2 ,4 ]
机构
[1] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Cent Lab, Shanghai 200433, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Huashan Hosp North, Dept Lab Med, Shanghai 200433, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Dermatol, Guangzhou 510275, Guangdong, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai 200433, Peoples R China
[5] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA
关键词
WORLD-HEALTH-ORGANIZATION; TYROSINE KINASE JAK2; EXON; 10; ESSENTIAL THROMBOCYTHEMIA; SENSITIVE DETECTION; MELTING ANALYSIS; MODIFIED PROBES; TIME; POLYMERASE; DNA;
D O I
10.1155/2014/458457
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A multiplex snapback primer system was developed for the simultaneous detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia chromosome-(Ph-) negative myeloproliferative neoplasms (MPNs). The multiplex system comprises two snapback versus limiting primer sets for JAK2 and MPL mutation enrichment and detection, respectively. Linear-After exponential (LATE) PCR strategy was employed for the primer design to maximize the amplification efficiency of the system. Low ionic strength buffer and rapid PCR protocol allowed for selective amplification of the mutant alleles. Amplification products were analyzed by melting curve analysis for mutation identification. The multiplex system archived 0.1% mutation load sensitivity and <5% coefficient of variation inter-/intra-assay reproducibility. 120 clinical samples were tested by the multiplex snapback primer assay, and verified with amplification refractory system (ARMS), quantitative PCR (qPCR) and Sanger sequencing method. The multiplex system, with a favored versatility, provided the molecular diagnosis of Ph-negative MPNs with a suitable implement and simplified the genetic test process.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Chip-based digital polymerase chain reaction technology is useful for monitoring the JAK2 V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
    Furuya, Daisuke
    Moriai, Mikako
    Murai, Ryosei
    Moriai, Ryosuke
    Koizumi, Yuki
    Endo, Teruo
    Asanuma, Kouichi
    Yanagihara, Nozomi
    Takahashi, Satoshi
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (05) : E113 - E116
  • [42] The clinical value of plasma CFDNA JAK2 V617F mutation detection in myeloproliferative neoplasms
    Wu, Q.
    Cao, G.
    Guan, M.
    CLINICA CHIMICA ACTA, 2024, 558
  • [43] THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS AND JAK2 V617F MUTATION POSITIVITY IN PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE DISEASES
    Unubol, M.
    Yavsoglu, I.
    Bozkurt, G.
    Kadikoylu, G.
    Bolaman, Z.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 590 - 590
  • [44] Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?
    Mehmet Sevki Uyanik
    Mehmet Baysal
    Gulsum Emel Pamuk
    Muhammet Maden
    Mustafa Akker
    Elif Gulsum Umit
    Muzaffer Demir
    Erkan Aydogdu
    Indian Journal of Hematology and Blood Transfusion, 2016, 32 : 262 - 267
  • [45] Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL
    Wang, Yan
    Ran, Fei
    Lin, Jin
    Zhang, Jing
    Ma, Dan
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [46] Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?
    Uyanik, Mehmet Sevki
    Baysal, Mehmet
    Pamuk, Gulsum Emel
    Maden, Muhammet
    Akker, Mustafa
    Umit, Elif Gulsum
    Demir, Muzaffer
    Aydogdu, Erkan
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2016, 32 (03) : 262 - 267
  • [47] Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL
    Wang, Yan
    Ran, Fei
    Lin, Jin
    Zhang, Jing
    Ma, Dan
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [48] JAK out of the box: myeloproliferative neoplasms-associated JAK2 V617F mutations contribute to aortic aneurysms
    Elf, Shannon E.
    HAEMATOLOGICA, 2021, 106 (07) : 1783 - 1784
  • [49] FREQUENCY OF JAK2 EXON 12 MUTATIONS IN JAK2 (V617F) NEGATIVE PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS (CMD)
    Bernardi, M.
    Ruggeri, M.
    Albiero, E.
    Madeo, D.
    Rodeghiero, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 294 - 294
  • [50] Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms
    Mambet, Cristina
    Babosova, Olga
    Defour, Jean-Philippe
    Leroy, Emilie
    Necula, Laura
    Stanca, Oana
    Tatic, Aurelia
    Berbec, Nicoleta
    Coriu, Daniel
    Belickova, Monika
    Kralova, Barbora
    Lanikova, Lucie
    Vesela, Jitka
    Pecquet, Christian
    Saussoy, Pascale
    Havelange, Violaine
    Diaconu, Carmen C.
    Divoky, Vladimir
    Constantinescu, Stefan N.
    BLOOD, 2018, 132 (25) : 2695 - 2699